Maxcyte, Inc.

Maxcyte, Inc. (MXCT) priced its initial public offering on Jul 30, 2021 at $13.00 per share, within its $11.50–$13.50 range, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.28B. TD Cowen was lead-left underwriter, joined by Stifel, William Blair and BTIG. Cooley advised the company and DLA Piper advised the underwriters.

MaxCyte, Inc. is a commercial cell engineering company providing platform technologies for cell-based research and cell therapy discovery, development and commercialization. Its Flow Electroporation platform introduces molecules into a wide range of cells using an electric field.

Status

IPO

Ticker

MXCT

Exchange

Nasdaq Global Select

Priced

Jul 30, 2021

IPO price

$13.00

Price range

$11.50–$13.50

Market cap at IPO price

$1.28B

First filed

Jul 9, 2021

Underwriters

TD Cowen, Stifel, William Blair and BTIG

Company counsel

Cooley

Underwriters' counsel

DLA Piper

Sector

Biotech & pharma

Country / state

MD

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.